258 completed, 62 terminated, 20 unknown, 16 recruiting. 160 Phase 2, 149 Phase 1, 39 Not applicable, 27 Phase 3, 3 Phase 4.
Follow Carcinogenesis: new trials by email Literature Review of Carcinogenesis trials Research Report on Carcinogenesis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| The Association Between Deep Endometriosis and the Occurrence of Colorectal Carcinoma Endometriosis, Deep Endometriosis | Not yet recruiting | University Medical Centre Ljubljana | 30 | 2026-02-01 | 2026-02-06 | |
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| The COOKER-BLADDER Trial Dietary regimens - Diet, Healthy, Urinary Bladder Diseases | Not applicable | Completed | Roland Seiler-Blarer | 13 | 2025-03-25 | 2025-12-11 |
| Microbiota and Carcinogenesis of Small-intestine Neuroendocrine Tumors Blood and stool sampling - Small-intestine Neuroendocrine Tumors | Recruiting | Hospices Civils de Lyon | 75 | 2024-11-05 | 2025-04-04 | |
| Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients Immunohistochemistry; WB; PCR - Clear Cell Renal Cell Carcinoma (ccRCC) | Completed | Shang Panfeng | 40 | 2024-07-01 | 2025-01-16 | |
| Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis. probiotic - H. Pylori Infection, Carcinogenesis | Not applicable | Active not recruiting | National Cheng-Kung University Hospital | 100 | 2024-03-20 | 2024-11-14 |
| Improvements in Thyroid Tumor Surgery and the Prognosis, Diagnosis, Recurrence and Metastasis of Patients Suturing the cervical linea alba during endoscopic thyroid surgery., Performing transcriptome sequencing - Papillary Thyroid Cancer, Lymph Node Metastasis | Not applicable | Unknown | Second Affiliated Hospital of Xi'an Jiaotong University | 170 | 2023-04-01 | 2024-06-21 |
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-07-06 |
| Early Detection of Cancer Onset Based on Sensing Field Cancerization at the Organ Level in the Alimentary Tract Using an Integrated Stimulated Raman/Scattering Modality for Endoscopic Real-time in Vivo Measurements SENSITIVE system - Esophageal Adenocarcinoma, Barrett Esophagus | Not applicable | Unknown | University Medical Center Groningen | 60 | 2022-07-01 | 2023-06-13 |
| Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg - Myeloproliferative Neoplasm | Phase 1 | Terminated | Joseph Jurcic | 2 | 2022-01-28 | 2024-04-23 |
| Switching to Potential Reduced Exposure Products in Adult Smokers ZYN - Tobacco Use Disorder, Oral Nicotine Pouch Use | Not applicable | Completed | Yale University | 30 | 2021-05-01 | 2024-05-01 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
| Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Bosutinib - Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia | Phase 1 / Phase 2 | Active not recruiting | Children's Oncology Group | 60 | 2020-07-06 | 2026-10-01 |
| Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia Decitabine, Ponatinib, Venetoclax - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 20 | 2020-05-17 | 2026-06-05 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine) - Hematologic Diseases, Acute Leukemia in Remission | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 43 | 2020-02-04 | 2026-01-27 |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Ponatinib - Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Incyte Biosciences International Sàrl | 70 | 2020-01-29 | 2026-10-09 |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab - Leukemia, Myeloid, Chronic, Myeloid Leukemia | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 242 | 2020-01-09 | 2025-11-05 |
Showing 20 of 382. Sign in to see all of them.
Blast Crisis (356) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (277) · Leukemia, Myeloid, Acute (263) · Leukemia, Myeloid, Accelerated Phase (244) · Leukemia (211) · Leukemia, Myeloid, Chronic-Phase (205) · Leukemia, Lymphocytic, Chronic, B-Cell (191) · Burkitt Lymphoma (178) · Lymphoma, Large B-Cell, Diffuse (172) · Lymphoma, Mantle-Cell (171) · Lymphoma, Non-Hodgkin (171) · Lymphoma, Follicular (170) · Myelodysplastic Syndromes (168) · Lymphoma, B-Cell, Marginal Zone (163) · Lymphoma, Large-Cell, Immunoblastic (163)
Neoplastic Processes (382) · Pathologic Processes (382) · Pathological Conditions, Signs and Symptoms (382) · Neoplasms by Histologic Type (363) · Disease Attributes (358) · Bone Marrow Diseases (356) · Cell Transformation, Neoplastic (356) · Chronic Disease (356) · Hemic and Lymphatic Diseases (356) · Hematologic Diseases (353) · Leukemia, Myeloid (351) · Neoplasms (344) · Immune System Diseases (289) · Immunoproliferative Disorders (287)
Cyclophosphamide (64) · Peripheral Blood Stem Cell Transplantation (58) · fludarabine phosphate (55) · Busulfan (44) · Tacrolimus (39) · Methotrexate (38) · Cytarabine (37) · Filgrastim (34) · Cyclosporine (33) · Mycophenolic Acid (33) · Antilymphocyte Serum (32) · Whole-Body Irradiation (28) · Radiotherapy (25) · Etoposide (22) · Imatinib Mesylate (22)
National Cancer Institute (NCI) (42) · Fred Hutchinson Cancer Center (41) · M.D. Anderson Cancer Center (30) · Memorial Sloan Kettering Cancer Center (18) · Case Comprehensive Cancer Center (14) · City of Hope Medical Center (12) · Masonic Cancer Center, University of Minnesota (8) · Roswell Park Cancer Institute (8) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · Jonsson Comprehensive Cancer Center (7) · OHSU Knight Cancer Institute (7) · Barbara Ann Karmanos Cancer Institute (6) · Novartis Pharmaceuticals (6) · University of Maryland, Baltimore (6) · Vanderbilt-Ingram Cancer Center (6)
United States (327) · Canada (21) · France (13) · Italy (13) · Germany (12) · South Korea (9) · Switzerland (8) · Belgium (7) · Taiwan (7) · United Kingdom (7) · China (5) · Netherlands (5) · Turkey (Türkiye) (5) · Israel (4) · Slovakia (4)
Judith E. Karp, MD (5) · Kyoo H. Lee, MD (5) · Brenda W. Cooper, MD (4) · Jorge Cortes (4) · Jorge Cortes, MD (4) · Ann E. Woolfrey, MD (3) · Claudio Anasetti, MD (3) · Claudio G. Brunstein, MD, PhD (3) · David G. Savage, MD (3) · Elias Jabbour (3) · Francis Giles (3) · Paul Martin (3) · Philip L. McCarthy, MD (3)
PMID 32499241, PMID 21715313, PMID 35007144, PMID 12114413, PMID 15107815, PMID 15459300, PMID 15466923, PMID 15570084, PMID 16278404, PMID 16775234, PMID 16880406, PMID 16885386, PMID 17397698, PMID 17562873, PMID 17640728, PMID 17910637, PMID 17971589, PMID 18327587, PMID 18571721, PMID 18698002, PMID 18769450, PMID 18838477, PMID 18989154, PMID 18997171, PMID 19139736, PMID 19170709, PMID 19179301, PMID 19270260, PMID 19286996, PMID 19344074, PMID 19706886, PMID 19841031, PMID 1994541, PMID 20124511, PMID 20460644, PMID 20466853, PMID 20511167, PMID 20858843, PMID 20860038, PMID 20952518, PMID 21403127, PMID 21508120, PMID 21523798, PMID 21719601, PMID 21791475, PMID 22002488, PMID 22009536, PMID 22154461, PMID 22157574, PMID 22430088
P30CA043703 (12), P30CA015704 (10), P30CA006973 (9), P30CA033572 (9), P30CA016672 (8), P30CA068485 (7), U01CA062461 (7), P01CA018029 (6), P30CA022453 (5), P30CA072720 (5), U01CA097452 (5), P30CA016086 (4), 2023 (3), N01CM62202 (3), P01CA015396 (3)